BRCA2 and non-Hodgkin lymphoma: For this, a relative risk of at least 4 was demonstrated for germline BRCA2 PGVs in a case-control study of medulloblastoma [64], an odds ratio (OR) of 3.6 for rhabdomyosarcoma [65], and an OR of 5.0 for paediatric and adolescent non-Hodgkin lymphoma, which intriguingly is not part of the cancer spectrum in classical HBOC and BRCA2-associated FA [66] (Table 1).